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Abstract. Atherosclerosis is a complex inflammatory 
disease involving cellular migration and interaction. Vas-
cular injury in response to different cardiovascular risk 
factors enhances endothelial dysfunction, which in turn 
promotes the expression of inflammatory markers and 
transendothelial leukocyte migration. Recruitment of 
leukocytes from the blood stream into the vessel intima is 
a crucial step for the development of the disease. Recent 
findings have highlighted the role of chemokines, che-
mokine receptors, adhesion molecules, and gap junctions 
in this process by acting as chemoattractant, adhesive, or 
intercellular communication molecules. In this short re-
view, we summarize new data concerning the different 
steps from leukocyte arrest to transendothelial migration 
and discuss potential new therapeutic approaches con-
cerning these processes.
Keywords. Atherosclerosis, leukocyte recruitment, cell adhesion molecule, chemokine, gap junction, therapeutic 
strategy.
Introduction
Atherosclerosis is a chronic inflammatory disease, re-
sponsible for the major causes of mortality, i.e. ischemic 
heart disease and cerebrovascular disease [1]. Although 
clinical damage appears in adult life, the pathology de-
velops during a long period, starting already in the child-
hood. Beside genetic risk factors, hyperlipidemia, diabe-
tes, hypertension, obesity, and smoking are the main car-
diovascular risk factors which enhance endothelial injury 
[2, 3]. Atherosclerosis affects the aorta focally, as well as 
carotid, coronary, iliac, and femoral arteries. The lesions 
are characterized by lipid accumulation, connective tis-
sue elements and immune infiltrates [4]. The inflamma-
tory process is determinant in all stages of atherosclero-
sis, from the formation of the early stage lesions through 
disease progression and finally to clinical complications 
[5]. Current treatment regimens against cardiovascular 
disease are mainly based on 3-hydroxy-3-methylglutaryl 
coenzyme A reductase inhibitors known as statins. These 
drugs improve cardiovascular outcome by their lipid-low-
ering, plaque-stabilizing, and anti-inflammatory effects. 
Versatile treatment options against the development of 
atherosclerosis are rare. Thus, a challenge for future re-
search is the identification and development of promising 
novel cholesterol-independent therapies.
Early atherosclerosis is characterized by endothelial dys-
function due to many risk factors. Under normal condi-
tions, endothelial cells inhibit platelet and leukocyte ad-
hesion to the vascular surface. Risk factors may initiate an 
inflammatory response in the artery wall [6, 7]. Activated 
endothelial cells switch their molecule expression pattern 
and, as a consequence, present several types of leukocyte 
adhesion molecules at their surface and secrete chemoat-
tractant molecules. These cellular changes cause leuko-
cyte rolling along the vascular surface and cell adhesion 
at the site of activation [8]. This endothelial dysfunction 
occurs preferentially at sites of hemodynamic strain. Low 
or oscillatory shear stress reduces the production of ni-
tric oxide (NO), increases expression of pro-inflamma-
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tory transcription factor NF-κB, enhances adhesion mol-
ecule expression and regulates the junctional molecule 
pattern in endothelial cells, all of which contributes to 
cellular transmigration at the atherosclerosis-prone site 
[9, 10]. Via secretion of cytokines, recruited leukocytes 
themselves amplify the ongoing chronic inflammatory 
process. This results in the presence of a large number 
of inflammatory and immune cells within atheroscle-
rotic lesions [11]. The involvement of leukocytes during 
atherogenesis has been extensively studied in different 
murine models of atherosclerosis. Mice deficient for the 
apolipoprotein E (ApoE–/–) or low-density lipoprotein 
receptor (LDLR–/–) genes fed with a high-cholesterol 
diet for only a few weeks develop atherosclerotic lesions 
comparable to those in humans. In ApoE knockout mice 
deficient also for the gene for macrophage colony-stimu-
lating factor (MCSF), the development of atherosclerotic 
lesions was reduced, and similar results were obtained in 
T cell-deficient LDLR knockout mice [12, 13]. The pres-
ence of monocyte/macrophages and T cells within ath-
erosclerotic lesions is the result of several specific bio-
logical processes. At the site of inflammation, circulating 
leukocytes roll along the vessel wall via selectin-carbo-
hydrate-mediated interactions with the endothelium. As 
a consequence, locally secreted chemokines mediate the 
arrest and transendothelial diapedesis of rolling leuko-
cytes. This later step also involves adhesion molecules 
such as integrins, members of the immunoglobulin family, 
as well as gap junctions. Migration of circulating mono-
cytes, T cells and, to a lesser extend, smooth muscle cells 
(SMCs) from the media lead to an accumulation of these 
cells within the vascular intima, resulting in neo-intima 
formation. These early chronic inflammatory processes 
lead to the formation of early atherosclerotic lesions, the 
fatty streak. Continuous recruitment of SMCs, together 
with proliferation of extracellular matrix components and 
accumulation of lipids characterize the following phases 
of atherosclerosis, fibrofatty and fibrous plaque forma-
tion [14]. Depending on the stability of the lesion, the 
plaque may rupture and induce thrombosis, leading to 
acute vascular events.
Adhesion molecules
Cell adhesion molecules (CAMs) are implicated in many 
inflammatory diseases such as multiple sclerosis, asthma 
and rheumatoid arthritis. In the pathology of atheroscle-
rosis, upregulation of adhesion molecule expression has 
been observed in animal models and humans [15–17]. 
Adhesion molecules are crucial mediators in the vari-
ous steps of leukocyte recruitment. Different subsets of 
adhesion molecules have been shown to be responsible 
for rolling and arrest of circulating inflammatory cells 
on the vascular endothelium [18]. The implication of dif-
ferent adhesion molecules at each step is schematized in 
Figure 1. This occurs via modulation of CAM expression 
on the surface of both the endothelial cells and the circu-
lating leukocytes. The molecules mediating these inter-
actions belong to four major protein families: selectins, 
selectin ligands, integrins, and members of the immuno-
globulin family.
Selectins, which induce leukocyte rolling and tethering, 
are carbohydrate-binding molecules, consisting of three 
subfamily members [19]. P-selectin, which is stored in 
Weibel-Palade bodies of endothelial cells and α-granules 
in platelets, is quickly translocated to the cell surface in 
response to pro-inflammatory stimuli [20]. P-selectin 
glycoprotein-1 (PSGL-1) is the principal ligand for P-
selectin, and binding of these two factors is crucial for 
the rolling of leukocytes at sites of inflammation [21]. 
E-selectin is not expressed under normal physiological 
conditions, but is synthesized and exported on the endo-
thelial cell surface in inflammatory situations [22]. Fi-
nally, L-selectin is expressed on all granulocytes, mono-
cytes, and on most lymphocytes [23]. Deficiency in E- 
and P-selectins leads to a strong decrease in the extent 
of atherosclerotic lesions (80%, 50%, and 45% after 8, 
22, and 37 weeks of a high-cholesterol diet, respectively) 
in LDLR–/– mice [24]. In vitro data have shown that the 
concentration of soluble CAMs correlates well with the 
expression of these molecules on the cell surface [25]. A 
recent study suggests that soluble P-selectin could be use-
ful to monitor disease progression in patients with coro-
nary artery disease (CAD) [26]. In contrast, the role of 
L-selectin in atherogenesis is not fully understood. Mice 
deficient for L-selectin have impaired leukocyte recruit-
ment into inflammatory sites [27]. According to the study 
of Eriksson et al. [28], L-selectin seems to play a role in 
the accumulation of circulating T cells during the disease. 
Recent data further suggest that a polymorphism of the 
L-selectin gene is implicated in human CAD [29].
Integrins and members of the immunoglobulin superfam-
ily are also involved in atherosclerotic leukocyte recruit-
ment since they mediate both adhesion and transmigra-
tion of leukocytes into the vessel wall. Integrins consist 
of a common β subunit, which is non-covalently linked 
with various α subunits. Blocking β1 integrin (VLA-4)/
ligand interaction in LDLR–/– mice reduces progression 
of atherosclerotic lesions [30]. Moreover, in mice lacking 
CD18, the β2 subunit, a 48% reduction of atherosclerotic 
lesions has been observed compared with controls [31].
Several repeating extracellular IgG-like domains, a trans-
membrane region and a short cytoplasmic domain char-
acterize the members of the immunoglobulin superfam-
ily [18]. Among these are the intercellular adhesion mol-
ecules-1, -2, -3 (ICAM-1, 2, 3), vascular cell adhesion 
molecule-1 (VCAM-1), and platelet endothelial cell ad-
hesion molecule-1 (PECAM-1). The biological function 
of these molecules is mainly to act as integrin receptors. 
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Inhibition of the interaction between adhesion molecules 
and their ligands decreases leukocyte adhesion, diapede-
sis, and, in some cases, also affects leukocyte rolling. In a 
mouse model of atherosclerosis, ICAM-1-deficient mice 
have been shown to be largely protected against the de-
velopment of atherosclerosis [32]. Moreover, these adhe-
sion molecules also circulate in serum as soluble forms, 
as a result of proteolytic cleavage or alternative splicing. 
The serum levels of P-selectin, ICAM-1, and VCAM-1 
are closely associated with the degree of atherosclerosis 
[33, 34] or different cardiovascular pathologies, such as 
myocardial infarction [35–37]. Thus, these soluble mol-
ecules may have potential value to predict atherosclerotic 
disease progression and future cardiovascular events.
Junctional adhesion molecules (JAMs) are members of 
the IgG superfamily and are localized in tight junctions 
and along the lateral membrane of epithelial cells. JAM 
proteins are also found in intercellular junctions of endo-
thelial cells and on the surface of leukocytes, platelets, 
and erythrocytes [38, 39]. The genetic deletion of JAM-A 
in ApoE-deficient mice reduced neointimal hyperplasia 
after wire injury of carotid arteries in association with 
lower macrophage infiltration into the neointima [40]. 
To substantiate the involvement of JAM-A in leukocyte 
recruitment, another study showed that soluble JAM-A 
could effectively inhibit distinct steps of mononuclear 
cell recruitment on inflamed or atherosclerotic endothe-
lium [41]. JAM-C is a counter-receptor for Mac-1, medi-
ating leukocyte-platelet interactions as well as leukocyte 
transendothelial migration. Recent findings point to a 
potential participation of endothelial JAM-C in the en-
hanced inflammatory cell recruitment during atheroscle-
rosis [42]. Thus, targeting JAMs in inflammatory disease 
could provide new therapeutic strategies.
Chemokines and chemokine receptors
Chemokines are small chemoattractant proteins known 
to induce leukocyte migration, growth, activation and to 
regulate leukocyte trafficking during inflammation [43, 
44]. However, this is not their only implication in cardio-
vascular diseases. Chemokines are also involved in the 
activation of platelets [45]. Thus, some chemokines seem 
to be implicated in neointimal hyperplasia, thrombus for-
mation as well as thrombogenic complication of native 
atherosclerosis [46]. Chemokines may also play a role in 
keeping macrophages within the lesion. By impeding the 
return of macrophages from the lesion to lymph nodes, 
chemokines increase the cellular apoptosis within the 
plaque and promote the atherogenesis. Many cell types 
including endothelial cells, SMCs, macrophages, and 
leukocytes can secrete them. Approximately 50 currently 
identified chemokines are classified in four subfamilies 
(C, CC, CXC, CX3C) according to the structural arrange-
ment of N-terminal conserved cysteine residues. Chemo-
Figure 1. Schematic representation of different steps in leukocyte recruitment from circulating cell-to-cell transmigration through the 
vascular endothelium, involving chemokines/chemokine receptors, adhesion molecules and gap junction molecules. ECs, endothelial cells; 
VCAM-1, vascular cell adhesion molecule-1; ICAM-1 intercellular adhesion molecules-1; PECAM-1, platelet endothelial cell adhesion 
molecule-1; JAM-A, junctional adhesion molecule-A; JAM-C, junctional adhesion molecule-C; Cx37, connexin37; Cx43, connexin43.
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kines need to bind their coupled receptors on target cells 
to induce cellular changes. Their receptors constitute a 
superfamily of 20 members, which possess seven trans-
membrane loops, coupled with heterotrimeric G proteins 
[47]. Besides the well-known, high-affinity binding of the 
chemokines to their receptors, a new concept implicating 
another interaction has emerged. This involves a low-af-
finity interaction with glycosaminoglycans (GAGs) on 
endothelial cells in the lumen of the blood vessel which 
seems to be essential for the functionality of chemokines 
[48]. Binding of the chemokines to GAGs prolongs their 
retention time under vascular flow conditions and allows 
the formation of localized gradients at inflammatory sites 
[49]. Moreover, this interaction promotes the presenta-
tion of the chemokines to their receptors.
The presence of chemokines and chemokine receptors 
within human and animal atherosclerotic lesions is well 
documented [50]. Secretion of chemokines can be in-
duced by different stimuli such as cytokines, oxidized lip-
ids, growth factors and vascular balloon injury [51]. The 
expression patterns of different chemokines change ac-
cording to the evolving atherosclerotic plaque. As shown 
in ApoE–/– mice, the progression of atherosclerotic le-
sion size correlates well with increased chemokine and 
chemokine receptor expression [52]. Monocyte chemo-
tactic protein-1 (MCP-1/CCL2) is a powerful chemoat-
tractant that is principally secreted by macrophages and, 
to a lesser extent, by activated endothelial cells and SMCs 
[53–55]. Gu et al. [56] have shown that MCP-1 deficiency 
in LDLR–/– mice leads to a significant reduction of the 
extent of the atherosclerotic lesion. In support of these 
findings, a deficiency in the MCP-1 binding receptor 
CCR2, which is highly expressed on monocytes, reduces 
the development of the disease in ApoE–/– mice [57, 58]. 
In these experiments, inhibition of disease progression 
was correlated with a decrease in relative macrophage 
content within the lesion. Two additional studies in exper-
imental mouse models provide further evidence for the 
crucial role of MCP-1 in atherogenesis. Over expression 
of MCP-1 was shown to induce local monocyte infiltra-
tion, and bone marrow transplantation of MCP-1-over-
expressing cells accelerated atherosclerosis in ApoE–/– 
mice [59]. Gene therapy studies using an amino-terminal 
deletion mutant of MCP-1 that binds CCR2 and thus 
blocks MCP-1-mediated monocyte chemotaxis, showed 
a reduction of plaque progression in ApoE–/– mice [60, 
61]. In humans, MCP-1 serum levels are correlated with 
the inflammatory activity in patients at risk of develop-
ing atherosclerosis [62]. Thus, MCP-1 serum levels may 
serve as a direct marker of CAD. Epidemiological studies 
investigated a possible role for a CCR2 polymorphism 
in cardiovascular disease and revealed conflicting results. 
Two groups suggested that a G to A gene substitution in 
the CCR2 gene is associated with an increased risk for 
myocardial infraction [63, 64]. In contrast, Gonzalez et 
al. [65] did not observe significant differences between 
patient and control groups.
Beside the fundamental role of MCP-1/CCR2 in athero-
genesis, several other members of the CC chemokine 
subfamily are also implicated in the disease. RANTES 
(regulated on activation normal T cell expressed and 
secreted/CCL5) plays a pivotal role in the recruitment 
of leukocytes [66]. Endothelial cells, SMCs, macro-
phages and activated T cells secrete RANTES within 
atherosclerotic lesions [67, 68]. In addition, others and 
we have shown that administration of an antagonist to 
the chemokine RANTES, Met-RANTES, can modulate 
inflammatory processes ongoing during atherosclerosis 
development. A first study showed that injection of Met-
RANTES inhibits neointima formation and macrophage 
infiltration in carotid arteries after wire-induced injury in 
ApoE–/– mice [69]. Our study showed that mice treated 
with Met-RANTES have fewer atherosclerotic lesions, 
and developing lesions are of a more stable phenotype 
[70]. RANTES binds to different chemokine receptors: 
CCR1, CCR3, and CCR5. The potential role of these re-
ceptors in atherosclerosis has been the subject of various 
investigations. Experiments using CCR5 deficiency in 
the context of atherosclerosis reported no significant dif-
ferences in lesion size between ApoE–/– mice that were 
also deficient in CCR5 and control mice. In this study, 
early atherosclerotic lesion development after 16 weeks 
of normal chow diet was investigated. However, our 
own more recent findings suggest that CCR5 may play 
an important role in the development of more advanced 
atherogenic lesions. We observed reduced lesion extent 
in ApoE–/–CCR5–/– mice after 10 weeks of high cho-
lesterol diet in comparison to control mice [unpublished 
data]. Finally, CCR5 deficiency has recently been shown 
to protect against neointima formation in atherosclerotic 
mice. The deletion of CCR5 upregulated the anti-inflam-
matory cytokine interleukin-10 (IL-10) and significantly 
reduced neointimal area after arterial injury, associated 
with a decrease in macrophage and T lymphocyte infil-
tration. In contrast, deletion of CCR1 in an experimental 
model of arterial injury did not affect neointimal area and 
cell content [71]. In experiments based on bone marrow 
transplantation, CCR1 disruption enhanced inflammation 
and atherosclerotic lesion development in LDLR–/– mice 
[72].
Other members of the CC chemokine subfamily which 
have been detected in human lesions are the macrophage 
inflammatory protein-1α and β (MIP-1α/CCL3 and MIP-
1β/CCL4) which are expressed by activated T cells [73]. 
In addition to their chemoattracting properties, MIP-1β 
and MCP-1 also act as pro-coagulant agents by binding 
to the CCR5 chemokine receptor on the surface of SMCs. 
They thereby induce an increase in tissue factor, the ini-
tiator of the coagulation cascade [74]. This mechanism 
likely plays an important role in arterial thrombosis. Fur-
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thermore, MCP-4/CCL13, I-309/CCL1, pulmonary and 
activation-regulated chemokine (PARC/CCL18), EBI1-
ligand chemokine (ELC/CCL19), and eotaxin/CCL11 
have also been found to be secreted by atheroma-associ-
ated cells [75–79].
Beside the members of the CC family, various chemokines 
from other subfamilies have also been found to be impli-
cated in atherosclerosis. Although most of them are pri-
marily neutrophil chemoattractors, some CXC and CX3C 
chemokines and their receptors have been detected in le-
sions and shown to play a role in atherogenesis. Among 
these, one of the most important is the chemokine IL-
8/CXCL8 and its corresponding receptor CXCR2, both 
of which are expressed in atherosclerotic lesions [80, 
81]. IL-8 acts as a chemoattractant and participates in 
several steps of leukocyte transmigration, from the roll-
ing to the arrest [82, 83]. Stromal cell-derived factor-1 
(SDF-1/CXCL12) is a potent chemoattractor for T cells 
and monocytes, and can arrest circulating lymphocytes 
[84]. It is highly expressed in atherosclerotic lesions and 
thought to be involved in atherogenesis [85]. Moreover, 
SDF-1 is also known to be implicated in platelet activa-
tion and may therefore participate in vascular thrombosis 
during plaque rupture [86]. Interferon (IFN)-γ -inducible 
protein-10 (IP-10/CXCL10), IFN-inducible T cell α che-
moattractant (I-TAC /CXCL11) and monokine induced 
by IFN-γ (Mig/CXCL9) are three IFN-γ -inducible che-
mokines that are expressed by atheroma-associated cells, 
but are not detectable in normal vessels. Endothelial cells, 
SMCs and macrophages all express IP-10, whereas Mig 
and I-TAC are mainly expressed in endothelial cells and 
macrophages. The differential expression pattern of these 
CXC chemokines by atheroma-associated cells plays a 
role in the recruitment and retention of activated T lym-
phocytes within vascular wall lesions during atherogen-
esis [87]. Their chemokine receptor CXCR3 is expressed 
by activated T cells in atherosclerotic lesions [87]. Inter-
estingly, we have shown in a recent study that double-
knockout mice for CXCR3 and ApoE fed a Western-type 
diet have reduced lesion development only in early steps 
of atherosclerosis compared with control ApoE–/– ani-
mals. However, no difference in advanced lesion forma-
tion was observed. In contrast, mice deficient for ApoE 
and CCR2 genes showed reduced lesion formation only 
at advanced stages of atherosclerosis. Triple-knockout 
mice for ApoE, CCR2, and CXCR3 seem to accumulate 
the effects of both receptor deficiencies. They display 
decreased plaque size at both early and advanced lesion 
stages, but without additional effects [58].
New findings indicate that the chemokine CXCL16 might 
be implicated in lipoprotein uptake by macrophages by 
acting as a scavanger receptor. This chemokine is ex-
pressed in soluble and transmembrane forms, binds to 
the CXCR6 chemokine receptor, and guides migration of 
activated T cells. Moreover, it is structurally identical to 
the scavenger receptor SR-PSOX, which mediates uptake 
of oxidized LDL. The pro-inflammatory cytokine IFN-γ 
enhances CXCL16 expression, as demonstrated in mice 
and in vitro in human monocytes [88]. Interestingly, a re-
cent clinical study revealed that lower plasma levels of 
CXCL16 are associated with CAD, indicating a potential 
atheroprotective function for CXCL16 [89].
Finally, fractalkine/CXC3CL1, which is the only CX3C 
chemokine, has been implicated in the pathology of ath-
erosclerosis. Fractalkine is the second chemokine ex-
pressed in both soluble and transmembrane forms. Con-
sequently, it could combine chemoattractant functions 
together with adhesion molecule properties. Its trans-
membrane form is expressed on endothelial cells under 
stimulation by pro-inflammatory molecules [90]. In its 
soluble form, fractalkine is a potent chemoattractant for 
monocytes and T cells. The first evidence relating frac-
talkine with atherosclerosis emerged from two epidemio-
logic studies. A polymorphism in the fractalkine receptor 
was associated with a lower risk for CAD, suggesting an 
involvement of this receptor in cardiovascular pathologies 
[91, 92]. Fractalkine has also been detected in human ath-
erosclerotic lesions [93] but not in normal arteries [94]. 
Additional relevant studies relating fractalkine and ath-
erosclerosis have been performed by genetic disruption 
of the fractalkine receptor, CX3CR1. Double-knockout 
mice for CX3CR1 and ApoE developed less atheroscle-
rosis compared with ApoE–/– controls, probably by in-
hibiting monocyte recruitment [95, 96]. A different set 
of experiments using fractalkine gene deficiency in an 
atherosclerotic mouse model dramatically reduced (85%) 
the lesion area in the brachiocephalic artery, but not in 
aortic roots [97]. The reduction in lesion size was associ-
ated with a reduced infiltration of monocytes.
The old understanding of the role of chemokines and their 
receptors, presenting apparent functional redundancy in 
atherosclerotic recruitment, is now changing to a more 
specialized interaction of chemokines to induce different 
specific steps of cellular recruitment. This new concept 
is still unsophisticated. Therefore, an important aim for 
the future will better characterization of the role of dif-
ferent chemokines and their receptors within the context 
of atherosclerosis.
Gap junctions
Recent data provide evidence that gap junctions not only 
play a role in intercellular communication but are also 
implicated in leukocyte recruitment and transmigration 
[98, 99]. Gap junctions enable intercellular communica-
tion. They consist of two hemichannels each composed 
of six connexins. Three connexins, namely Cx37, Cx40 
and Cx43 have been detected in vascular endothelial cells 
[100]. The first potential implication of connexins in 
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atherosclerosis was shown by Polacek et al. [101]. They 
found that Cx43 is strongly expressed in macrophage 
foam cells in human atherosclerotic carotid arteries. To 
extend their own findings, they demonstrated that Cx43 
expression is upregulated in macrophage foam cells and 
downregulated in medial SMCs [102]. We demonstrated 
that Cx37, Cx40, and Cx43 are differentially expressed 
within human and mouse atherosclerotic lesions [103]. 
Human Cx37 genetic polymorphisms have been associ-
ated with CAD and/or myocardial infarction [104–107]. 
Cx37–/–, ApoE–/– mice developed more atherosclerosis 
than Cx37+/+, ApoE–/– control mice, indicating that 
Cx37 is atheroprotective [108]. Moreover, the authors 
observed that monocyte recruitment was enhanced in the 
absence of Cx37 on macrophages but not on the endothe-
lium. In a different set of experiments, we showed that 
LDLR–/– mice with a reduction of Cx43 expression de-
velop less atherosclerosis [109, 110]. Recently, Cx43 has 
been implicated in the monocyte/macrophage infiltration 
within atherosclerotic lesions in a model of carotid bal-
loon injury in LDLR–/– mice [111]. These results and the 
fact that monocyte/macrophage but not lymphocyte dia-
pedesis is significantly reduced by decreasing Cx43 [112, 
113] and a lack of Cx37 increases monocyte recruitment 
suggest that modification of intercellular communication 
via gap junctions is likely to contribute to the process of 
atherogenesis. Development of novel strategies inhibiting 
Cx43 expression or maybe increasing Cx37 on monocyte/
macrophages could be potential effective therapies.
Future therapeutic strategies
Atherosclerosis involves both immune and inflamma-
tory processes. Endothelial dysfunction due to different 
risk factors triggers inflammatory cell recruitment into 
the intima. Activated monocyte/macrophages and T cells 
secrete pro-inflammatory molecules that enhance new 
leukocyte arrest and diapedesis at the lesion site. To stop 
this chronic inflammatory process, new therapeutic strat-
egies have to be investigated. Beyond reducing risk fac-
tors through improved life habits and cholesterol-lower-
ing drugs, anti-inflammatory treatments seem to be the 
most promising therapies. In particular, impeding cellu-
lar recruitment at sites of vascular inflammation could 
be a future effective treatment. However, the benefit of 
such approaches is controversial. There are different 
limitations of immunosuppressive treatments that reduce 
leukocyte recruitment. First, clinical manifestations of 
atherosclerosis appear at advanced stages of the disease. 
Thus, therapies must be validated on pre-established le-
sions. Second, treatments impeding leukocyte adhesion 
or/and migration should specifically target atheroscle-
rotic lesions without affecting the general host defence. 
Third, given the long development of the disease, anti-in-
flammatory treatments should not be administrated over 
the long term, to avoid potential adverse side-effects. To 
overcome these limitations, a system of local drug deliv-
ery could be considered. Contrary to systemic treatment, 
local drug administration avoids adverse side-effects, 
including immunosuppression. This kind of treatment 
could conceivably be applied by percutaneous coronary 
intervention. Another promising technology to selectively 
target specific cell types could be viral gene delivery. For 
example, genes encoding inhibitors of adhesion molecule 
or chemokine expression could be selectively delivered to 
activated endothelium.
Adhesion molecule/ligand interactions may be a useful 
therapeutic target for several reasons. Adhesion mole-
cules are expressed in pro-atherogenic conditions and are 
essential for leukocyte rolling and arrest. However, ad-
hesion molecules are principally involved in fatty streak 
formation. They may therefore be inappropriate targets 
for treatment at the advanced atherosclerotic lesion stage, 
but could be very useful to prevent the initiation of lesion 
development. Considerable progress has been realized in 
the development of several inhibitors of adhesion mol-
ecule expression. However, it is difficult to extrapolate 
these potential therapies to clinical use because animal 
models do not necessarily present a similar pathology to 
humans. Thus, further investigations to test a potential 
therapeutic use of these inhibitors are warranted. In addi-
tion to a potential therapeutic benefit, blood serum levels 
of soluble adhesion molecules could be used as a cardio-
vascular risk marker.
The latest findings in animal models suggest that block-
ing chemokinereceptor interactions may serve as a 
suitable approach to treat atherosclerosis. With a better 
knowledge of chemokine effects on specific cell sub-
types, blocking chemokine interaction could be of thera-
peutic use to reduce inflammatory cell recruitment within 
atherosclerotic lesions and impede chronic inflammatory 
processes. Using antagonists or analogous molecules to 
modulate the recruitment of a specific cellular subtype 
of leukocyte within the lesion may be imaginable as a 
potential treatment. By selectively inhibiting the diape-
desis of pro-inflammatory leukocytes and enhancing the 
recruitment of anti-inflammatory cells like regulatory T 
cells, it is conceivable to reverse the chronic inflamma-
tory process and to promote a more stable lesion that is 
less subject to rupture. Indeed, recent findings showed 
that the transfer of regulatory T cells into atherosclerotic 
mice inhibits disease progression [114]. Thus, inducing 
regulatory T cells might represent an attractive tool for 
the treatment of atherosclerosis. With a better knowledge 
of underlying mechanisms, we could imagine a mul-
tiple treatment strategy that inhibits the recruitment of 
pro-inflammatory leukocytes and, in parallel, enhances 
the infiltration of regulatory T cells to lesion sites. The 
regulatory T cells might counteract the process of chronic 
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inflammation, thereby restoring a balance between pro- 
and anti-inflammatory mediators.
Studies demonstrating the involvement of connexins in 
atherosclerosis may also open new therapeutic strategies 
affecting paracrine cell-cell interactions and junctional 
intercellular communication to reduce the evolution of 
cardiovascular disease. Modulating the expression pat-
tern or functional activity of connexins, for example with 
Cx-specific blocking peptides or antisense mRNA, might 
serve as a new therapeutic approach to reduce the pro-
gression of atherosclerosis.
Compounds that inhibit leukocyte recruitment could be 
particularly interesting for the treatment of ischemia/re-
perfusion disease. Myocardial ischemia is the major con-
sequence of atherosclerosis. Animal models of sustained 
ischemia have shown exacerbation of myocardial injury 
early during reperfusion, mediated in large part by in-
flammatory processes. A massive neutrophil and mono-
cyte/macrophage recruitment occurs during reperfusion. 
Reducing this cell infiltration via selective inhibitors 
could be an effective therapy to reduce reperfusion dam-
age. Importantly, contrary to atherogenesis, infiltration 
of inflammatory cells within ischemic tissues is a short-
term process. Thus, a major clinical improvement might 
be achieved by short-term treatment, without potential 
adverse effects of a systemic long-term therapy.
Further in vitro and in vivo investigations are needed to 
establish the potential clinical use of molecules inhibiting 
leukocyte recruitment. Recent findings in this field may 
help to identify new drugs against atherogenesis or isch-
emia/reperfusion and other inflammatory diseases, such 
as rheumatoid arthritis or multiple sclerosis.
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